계명대학교 의학도서관 Repository

A multi-center and non-interventional registry of brentuximab vedotin in patients with relapsed or refractory CD30-positive lymphoma: the CISL1803/BRAVO study

Metadata Downloads
Author(s)
Seok Jin KimYoung Rok DoHo-Sup LeeWon-Sik LeeJee Hyun KongJae-Yong KwakHyeon-Seok EomJoon Ho MoonJun Ho YiJeong-Ok LeeJae-Cheol JoDeok-Hwan Yang
Keimyung Author(s)
Do, Young Rok
Department
Dept. of Internal Medicine (내과학)
Journal Title
Blood Res
Issued Date
2023
Volume
58
Issue
4
Keyword
Brentuximab vedotinCD30LymphomaOutcome
Abstract
Background:
Brentuximab vedotin (BV), a potent antibody-drug conjugate, targets the CD30 antigen. In Korea, BV has been approved for the treatment of relapsed or refractory Hodgkin lymphoma (HL), anaplastic large-cell lymphoma (ALCL), and cutaneous T-cell lymphomas, including mycosis fungoides (MF). However, there are limited data reflecting real-world experiences with BV treatment for HL, ALCL, and MF.

Methods:
This was a multicenter, non-interventional registry study of the efficacy and safety of BV in patients with relapsed or refractory CD30-positive lymphoma (CISL1803/BRAVO). Outcomes were determined based on the occurrence of relapse or progression and overall survival after BV treatment.

Results:
A total of 85 patients were enrolled in this study. The median number of BV cycles was 10 (range, 2‒16) in the patients with HL. The objective response rate (ORR) of patients with HL to BV was 85.4% (41/48), comprising 27 complete responses (CRs) and 14 partial responses (PRs). The ORR of ALCL was 88% (22/25), consisting of 17 CRs and five PRs, whereas the ORR of MF was 92% (11/12). At the median follow-up of 44.6 months after BV treatment, the median post-BV progression-free survival of HL, ALCL, and MF patients was 23.6 months, 29.0 months, and 16.7 months, respectively (P=0.641). The most common side effect of BV was peripheral neuropathy; 22 patients (25.9%, 22/85) experienced peripheral neuropathy (all grades).

Conclusion:
The treatment outcomes of patients with relapsed or refractory CD30-positive lymphoma improved with BV treatment, and the safety profile was manageable.
Keimyung Author(s)(Kor)
도영록
Publisher
School of Medicine (의과대학)
Type
Article
ISSN
2288-0011
Source
https://www.bloodresearch.or.kr/journal/view.html?doi=10.5045/br.2023.2023206
DOI
10.5045/br.2023.2023206
URI
https://kumel.medlib.dsmc.or.kr/handle/2015.oak/45316
Appears in Collections:
1. School of Medicine (의과대학) > Dept. of Internal Medicine (내과학)
공개 및 라이선스
  • 공개 구분공개
파일 목록

Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.